November 7, 2024 10:53 AM EST
News Briefing

Geron’s roy­al­ty deal; Minghui’s new VEGF bis­pe­cif­ic da­ta

ENDPOINTS

Plus, news about ADC Ther­a­peu­tics, Celldex and Virac­ta Ther­a­peu­tics:

Geron inks up to $375M roy­al­ty and debt deal: The com­pa­ny now

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

De­nali teas­es ear­ly da­ta for en­zyme re­place­ment ther­a­py in rare dis­ease

Gen­mab chops ear­ly can­cer prospects to pri­or­i­tize Phase 3 projects

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times